RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      Posaconazole versus Itraconazole as Prophylactic Antifungal Agents during Induction Chemotherapy for Acute Myeloid Leukemia: A Real-World Single Center Comparison

      한글로보기

      https://www.riss.kr/link?id=A106987379

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Objective: To prevent invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients, the use of posaconazole as a prophylactic
      antifungal agent has become standard in patients undergoing induction chemotherapy. However, there are few data comparing
      itraconazole and posaconazole as prophylactic antifungal agents in the real world.
      Methods: Patients at the Soonchunhyang University Seoul Hospital, who were treated with itraconazole or posaconazole for preventing
      IFD during induction chemotherapy for AML from January 2009 to April 2018, were included in the study. The collected
      clinical data were reviewed, and IFD was diagnosed using the revised definition of IFD from the European Organization for Research
      and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases
      Mycoses Study Group.
      Results: A total of 53 patients were recruited to receive either posaconazole (n=29) or itraconazole (n=24). IFD occurred in seven
      patients (29.1%) who used posaconazole and in six patients (20.6%) who used itraconazole for antifungal prophylaxis (P=0.475).
      The 100-day mortality rate was 4 (13.8%) in the posaconazole group and 2 (8.3%) in the itraconazole group (P=0.535).
      Conclusion: There was no significant difference in the incidence of IFD and 100-day mortality between the patients with induction
      chemotherapy for newly diagnosed AML who received posaconazole and itraconazole as prophylactic antifungal agents. These results
      suggest that it would be worthwhile to ascertain whether posaconazole is widely known as a better approach than itraconazole
      as prophylactic antifungal agents in the real-world.
      번역하기

      Objective: To prevent invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients, the use of posaconazole as a prophylactic antifungal agent has become standard in patients undergoing induction chemotherapy. However, there are few data com...

      Objective: To prevent invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients, the use of posaconazole as a prophylactic
      antifungal agent has become standard in patients undergoing induction chemotherapy. However, there are few data comparing
      itraconazole and posaconazole as prophylactic antifungal agents in the real world.
      Methods: Patients at the Soonchunhyang University Seoul Hospital, who were treated with itraconazole or posaconazole for preventing
      IFD during induction chemotherapy for AML from January 2009 to April 2018, were included in the study. The collected
      clinical data were reviewed, and IFD was diagnosed using the revised definition of IFD from the European Organization for Research
      and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases
      Mycoses Study Group.
      Results: A total of 53 patients were recruited to receive either posaconazole (n=29) or itraconazole (n=24). IFD occurred in seven
      patients (29.1%) who used posaconazole and in six patients (20.6%) who used itraconazole for antifungal prophylaxis (P=0.475).
      The 100-day mortality rate was 4 (13.8%) in the posaconazole group and 2 (8.3%) in the itraconazole group (P=0.535).
      Conclusion: There was no significant difference in the incidence of IFD and 100-day mortality between the patients with induction
      chemotherapy for newly diagnosed AML who received posaconazole and itraconazole as prophylactic antifungal agents. These results
      suggest that it would be worthwhile to ascertain whether posaconazole is widely known as a better approach than itraconazole
      as prophylactic antifungal agents in the real-world.

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼